Recombinant human IgG antibodies against human cytomegalovirus

Biomedical and Environmental Sciences

Volumn 21, Issue 5, 2008, Pages 372-380

  Duan, Tao ^a   Wang, Xiao Fang ^a   Xiao, Shu Yuan ^b   Gu, Shu Yan ^b   Liang, Mi Fang ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Human cytomegalovirus; Human engineering antibody; Phage display; Recombinant baculovirus expression

Indexed keywords

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 57249110675     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-3988(08)60057-4     Document Type: Article

References (35)

1. Plummer G. (1973). Cytomegaloviruses of man and animals. Prog Med Virol 15, 92-125.
2. Smith M G (1954). Propagation of salivary gland virus of the mouse in tissue cultures. Proc Soc Exp Biol Med 86, 435-440.
3. Li C R, Greenberg P D, Gilbert M J, et al. (1994). Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of gancicrovir prophylaxis. Blood 83, 1971-1979.
4. Conti D J, Shen G, Singh T, et al. (1997). Ganciclovir prophylaxis of cytomegalovirus disease. Transplant Proc 29, 804-806.
5. Gonczol E, Berencsi K, Pincus S, et al. (1995). Preclinical evaluation of an ALVAC (canarypox): human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13, 1080-1085.
6. Gonczol E, Plotkin S (2001). Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 1, 401-412.
7. Snydman D R, Falagas M E, Avery R, et al. (2001). Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 33, 2571-2575.
8. Snydman D R, Werner B G, Dougherty N N, et al. (1994). A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 26(5 Suppl 1), 23-27.
9. Snydman D R, Werner B G, Dougherty N N, et al. (1993). Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Annals of Internal Medicine 119, 984-991.
10. Snydman D R (1990). Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 12(Suppl 7), S839-848.
11. Borucki M J, Spritzler J, Asmuth D M, et al. (2004). A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res 64, 103-111.
12. Pollard R, Nokta M, Pappas P, et al. (1992). A phase I/IIA study of a human monoclonal anti-cytomegalovirus antibody in patients with AIDS. Antiviral Res 17, 111.
13. Lakeman F, Blevins C, Whitley R, et al. (1991). In vitro neutralization of cytomegalovirus strain by a human monoclonal antibody, MSL-109 (abstract). Antiviral Res 15, (Suppl. 1), 77.
14. Barbas C F III, Hu D, Dunlop N, et al. (1994). In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci 91, 3809-3813.
15. Burioni R, Williamson R A, Sanna P P, et al. (1994). Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc Natl Acad Sci 91, 355-359.
16. Sanna P P, Williamson R A, De L A, et al. (1995). Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. Proc Natl Acad Sci 92, 6439-6443.
17. Robinson R F, Nahata M C (2000). Respiratory sgucytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health Syst Pharm 57, 259-264.
18. Goncalvez A P, Men R, Wernly C, et al. (2004). Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol 78, 12910-12918.
19. Men R, Yamashiro T, Goncalvez A P, et al. (2004). Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin Gl antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 78, 4665-4674.
20. Liang M, Mahler M, Koch J, et al. (2003). Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J Med Virol 69, 99-107.
21. Koch J, Liang M, Queitsch I, et al. (2003). Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology 308, 64-73.
22. Duan T, Liang M, Gu S (2003). Human anti-HCMV neutralizing Fab antibody generated by phage display library. Chinese Journal of Experimental and Clinical Virology 17, 247-250. (In Chinese)
23. Nejatollahi F, Hodgetts S J, Vallely P J, et al. (2002). Human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol Med Microbiol 15, 237-244.
24. Takekoshi M, Maeda F, Tachibana H, et al. (1998). Human monoclonal anti-HCMV neutralizing antibody from phage display libraries. J Virol Methods 74, 89-98.
25. Williamson R A, Burioni R, Sanna P P, et al. (1993). Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci 90, 4141-4145.
26. Liang M, Dübel S, Li D, et al. (2001). Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J Immunol MetH 247, 119-130.
27. Liang M, Dübel S (2001). Expression of antibody fragments using the Baculovirus system. In: Antibody Engineering, ed: Kontermann, R. and Dübel, S. Springer Verlag, Heidelberg.
28. Britt M J, Mach M (1996). Human cytomegalovirus glycoproteins. Intervirology 39, 401-412.
29. Spaete R R, Gehrz R C, Landini M P (1994). Human cytomegalovirus structural proteins. J Gen Virol 75, 3287-3308.
30. Rasmussen L E, Nelson R M, Kelsall D C, et al. (1984). Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci 81, 876-880.
31. Barbas C F III, Burton, Dennis R (1991). Monoclonal antibodies from combinatorial libraries. Cold Spring Harbor Laboratory Cousre.
32. Zhou G Y, Bernard R (2002). Truncated forms of glycoprotein D of herpes simlex virus 1 capable of blocking apotosis and of low-efficiency entry into cell form a heterodimer dependent on the presence of a cysteine located in the shared transmembrane domains. J Virol 76, 11469-11475.
33. Joassin L, Somze A, Register M (1989). Detection by enzyme-linked immunosorbent assay of specific immunoglobulin G isotypes in primary and established cytomegalovirus infections. J Clin Microbiol 27, 139-144.
34. Vey M, Schafer W, Reis B, et al. (1995). Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin. Virology 206, 746-749.
35. Lopes F B, Colaco S, May J S, et al. (2004). Characterization of Murine Gammaherpesvirus 68 Glycoprotein B. J Virol 78, 13370-13375.